JSC

Market Access

Unlocking oncology access: What the OECD findings mean for m...

New policies are shaping the market access landscape, such as the introduction of the EU HTA for oncology medicines.

Market Access

Early strategic evidence planning is a key success factor in...

As the European Union (EU) ushers in a new era of health technology regulation, pharmaceutical companies face both unprecedented challenges and opportunities.

News

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks